Lingua: Inglese
Editore: LAP LAMBERT Academic Publishing, 2018
ISBN 10: 6139851009 ISBN 13: 9786139851003
Da: Books Puddle, New York, NY, U.S.A.
Condizione: New.
Lingua: Inglese
Editore: LAP LAMBERT Academic Publishing, 2018
ISBN 10: 6139851009 ISBN 13: 9786139851003
Da: preigu, Osnabrück, Germania
EUR 33,20
Quantità: 5 disponibili
Aggiungi al carrelloTaschenbuch. Condizione: Neu. Intellectual Property Rights: Abstract Book | Anju Goyal (u. a.) | Taschenbuch | 64 S. | Englisch | 2018 | LAP LAMBERT Academic Publishing | EAN 9786139851003 | Verantwortliche Person für die EU: preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, mail[at]preigu[dot]de | Anbieter: preigu.
Lingua: Inglese
Editore: LAP LAMBERT Academic Publishing, 2018
ISBN 10: 6139851009 ISBN 13: 9786139851003
Da: Mispah books, Redhill, SURRE, Regno Unito
EUR 135,72
Quantità: 1 disponibili
Aggiungi al carrellopaperback. Condizione: New. NEW. SHIPS FROM MULTIPLE LOCATIONS. book.
Lingua: Inglese
Editore: LAP LAMBERT Academic Publishing Jun 2018, 2018
ISBN 10: 6139851009 ISBN 13: 9786139851003
Da: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germania
EUR 35,90
Quantità: 2 disponibili
Aggiungi al carrelloTaschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Pharmaceuticals have brought immense health benefits to developing countries, but one third of the world's population does not have access to existing essential drugs. The Commission on Health Research for Development (1990) showed that less than 10 per cent of global health research is directed towards diseases that afflict 90% of the world's population. IPRs in pharmaceuticals have two principal areas of impact which affect public health. First, there is the issue of access, where discussion focuses on the links between IPRs, exclusion of competitors and the availability and pricing of new medicines. Second, there is the issue of incentive innovation, where discussion focuses on the role of IPRs in motivating R&D and marketing of new drugs and the effect of IPRs on R&D expenditure and its allocation across diseases, countries and organizations. 64 pp. Englisch.
Lingua: Inglese
Editore: LAP LAMBERT Academic Publishing, 2018
ISBN 10: 6139851009 ISBN 13: 9786139851003
Da: Majestic Books, Hounslow, Regno Unito
EUR 57,46
Quantità: 4 disponibili
Aggiungi al carrelloCondizione: New. Print on Demand.
Lingua: Inglese
Editore: LAP LAMBERT Academic Publishing, 2018
ISBN 10: 6139851009 ISBN 13: 9786139851003
Da: Biblios, Frankfurt am main, HESSE, Germania
EUR 58,27
Quantità: 4 disponibili
Aggiungi al carrelloCondizione: New. PRINT ON DEMAND.
Lingua: Inglese
Editore: LAP LAMBERT Academic Publishing, 2018
ISBN 10: 6139851009 ISBN 13: 9786139851003
Da: moluna, Greven, Germania
EUR 31,27
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Goyal AnjuDr Anju Goyal is Professor in Pharmaceutical Chemistry and Head of Department of Pharmaceutical Quality Assurance at BN Institute of Pharmaceutical Sciences, Udaipur. Dr Kamal Singh Rathore is Head of Department at Pharmace.
Lingua: Inglese
Editore: LAP LAMBERT Academic Publishing Jun 2018, 2018
ISBN 10: 6139851009 ISBN 13: 9786139851003
Da: buchversandmimpf2000, Emtmannsberg, BAYE, Germania
EUR 35,90
Quantità: 1 disponibili
Aggiungi al carrelloTaschenbuch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Pharmaceuticals have brought immense health benefits to developing countries, but one third of the world's population does not have access to existing essential drugs. The Commission on Health Research for Development (1990) showed that less than 10 per cent of global health research is directed towards diseases that afflict 90% of the world's population. IPRs in pharmaceuticals have two principal areas of impact which affect public health. First, there is the issue of access, where discussion focuses on the links between IPRs, exclusion of competitors and the availability and pricing of new medicines. Second, there is the issue of incentive innovation, where discussion focuses on the role of IPRs in motivating R&D and marketing of new drugs and the effect of IPRs on R&D expenditure and its allocation across diseases, countries and organizations.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 64 pp. Englisch.
Lingua: Inglese
Editore: LAP LAMBERT Academic Publishing, 2018
ISBN 10: 6139851009 ISBN 13: 9786139851003
Da: AHA-BUCH GmbH, Einbeck, Germania
EUR 37,20
Quantità: 1 disponibili
Aggiungi al carrelloTaschenbuch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Pharmaceuticals have brought immense health benefits to developing countries, but one third of the world's population does not have access to existing essential drugs. The Commission on Health Research for Development (1990) showed that less than 10 per cent of global health research is directed towards diseases that afflict 90% of the world's population. IPRs in pharmaceuticals have two principal areas of impact which affect public health. First, there is the issue of access, where discussion focuses on the links between IPRs, exclusion of competitors and the availability and pricing of new medicines. Second, there is the issue of incentive innovation, where discussion focuses on the role of IPRs in motivating R&D and marketing of new drugs and the effect of IPRs on R&D expenditure and its allocation across diseases, countries and organizations.